Table 5.
Clinical-Molecular Prognostic Scores in Polycythemia Vera and Essential Thrombocythemia
| Prognostic Score | Variables (Points) | Risk Categories (Points) | Median Survival (Years) |
|---|---|---|---|
| MIPSS-PV Tefferi et al55 |
Leukocyte count ≥15 x 109/L (1) Thrombosis history (1) Age >67 years (2) SRSF2 mutation (3) |
Low (0–1) Intermediate (2–3) High (4–7) |
24 13.1 3.2 |
| MIPSS-ET Tefferi et al55 |
Leukocyte count ≥11 x 109/L (1) Age >60 years (4) Male sex (1) SRSF2, SF3B1, U2AF1 and TP53 mutation (2) |
Low (0–1) Intermediate (2–5) High (6–8) |
34.3 14.1 7.9 |
Note: In bold molecular variables.
Abbreviations: MIPSS, Mutation-Enhanced International Prognostic Scoring System, PV, polycythemia vera; ET, essential thrombocythemia.